Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

← catalyst calendar

NCT05652205 · results posted

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With Ironwood Pharmaceuticals, Inc..

Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
123actual
Sites
48
Countries
Bulgaria, Netherlands, United Kingdom +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-12-29actualWhen the study began enrolling
Primary completion2025-09-02actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-09-02actualThe whole study's end, after follow-up
First posted2022-12-15actualWhen this record first appeared on the registry
Results posted2026-05-14actualWhen the sponsor posted results to the registry
Record updated2026-05-14actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Functional Constipation (FC)
  • Chronic Idiopathic Constipation (CIC)

Interventions

  • Drug: Placebo for Linaclotide
  • Drug: Linaclotide

Primary outcomes

what the primary-completion date above is the date OF
Change From Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) Observed by the Primary Caregiver During the Double-blind Study Intervention Period
measured Baseline to Week 12
Number of Participants With Treatment-Emergent Adverse Events
measured From the time of study drug administration until 30 days or 5 half-lives after the last dose, up to 126 days in Period 1 and 226 days in Period 2

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2025-02-20 · 4.4 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-04-02 · 484 KB · SAP_001.pdf

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed